Assessment of Personalized Follow-up in Prevention of Type 2 Diabetes
In France, the overall prevalence of diabetes was estimated at 5% of population in 2016, type 2 diabetes (T2DM) corresponding to 90% of cases. However, this figure is greatly underestimated,since it does not take into account people who are untreated or not diagnosed. However,it is estimated that 20 to 30% of adults wi
| Condition(s) | Diabete Type 2 |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | In France, the overall prevalence of diabetes was estimated at 5% of population in 2016, type 2 diabetes (T2DM) corresponding to 90% of cases. However, this figure is greatly underestimated,since it does not take into account people who are untreated or not diagnosed. However,it is estimated that 20 to 30% of adults with diabetes do not are not diagnosed. Conclusions presented during the annual meeting of the european Association for the Study of diabetes (EASD-Berlin) from 2019 suggest that signs precursors of the disease would be present up to 20 years before the diagnosis. The Diagnosis is usually made around 40-50 years. The main factor of risk of T2D is the lifestyle, in particular a diet too rich for a too sedentary daily life. From a medico-economic point of view, chronic pathologie |
| Who can participate | Inclusion Criteria: * Patient, male or female, over the age of 18 * Patient with a FINDRISC score ≥10 points * Beneficiary of a French health insurance system * Patient having been informed and having given their consent free, enlightened and written Exclusion Criteria: * Patient over 75 years old * Patient already diagnosed with type 2 diabetes * Patient whose physical and/or psychological health is severely impaired, which according to the investigator may affect the compliance of the study participant. * Patient participating in another research * Patient in period of exclusion from another research always in progress at the time of inclusion. * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by court order or administration. * Pre |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Ramsay Générale de Santé |
| Locations | Biarritz, Aquitaine, France |
| Start date | 2022-03-20 |
| NCT ID | NCT05325710 |
| Official listing | https://clinicaltrials.gov/study/NCT05325710 |